Synvisc-one syringe 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26F7WWL
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,283
Award facts
- Contract value 100% obligated
- $12,282.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 14, 2026, the Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. Valued at $12,282.84 with a firm fixed-price structure, this non-set-aside delivery order is scheduled for completion by January 15, 2026, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a task order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement. The company's federal contract portfolio demonstrates extensive capability in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. All of the company's reviewed federal contract awards have been competitively awarded without set-aside designations, reflecting its demonstrated ability to meet federal procurement requirements through open competition. Through the SPE2DX IDC, AmerisourceBergen supports military treatment facilities, veterans' healthcare programs, and other federal medical institutions with essential pharmaceutical and medical supplies on a global basis.
Quick answers
Who was awarded contract SPE2DR26F7WWL?
SPE2DR26F7WWL was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F7WWL worth?
The government has obligated $12,283 on SPE2DR26F7WWL.
Is contract SPE2DR26F7WWL an order under another contract?
Yes. SPE2DR26F7WWL is a delivery order under SPE2DR25D7061, an indefinite delivery contract.
Was contract SPE2DR26F7WWL competed?
The extent of competition for SPE2DR26F7WWL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award